|
|
Article: BioAdvance Funds TREVENTIS to Advance Alzheimer's Drug Discovery.
- Article from:
- Business Wire
- Article date:
- August 10, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PHILADELPHIA -- BioAdvance, the Biotechnology Greenhouse Corporation of Southeastern Pennsylvania, announced today a $550,000 seed-stage investment in TREVENTIS Corporation, an emerging life sciences company in Southeastern Pennsylvania.
TREVENTIS is focused on developing disease-modifying small molecule drugs and diagnostics for early stage treatment of Alzheimer's disease (AD) and other major neurodegenerative disorders. The Company's proprietary discovery technology targets protein misfolding to inhibit the aggregation of amyloid proteins, including beta-amyloid (plaque) and tau proteins (tangles), both associated with the neuronal loss in Alzheimer's disease. ...